LND vs. AVO, FDP, TED, ARCM, GSP, PREM, ARS, KAV, POW, and CLA
Should you be buying Landore Resources stock or one of its competitors? The main competitors of Landore Resources include Advanced Oncotherapy (AVO), FD Technologies (FDP), Ted Baker (TED), Arc Minerals (ARCM), Gensource Potash (GSP), Premier African Minerals (PREM), Asiamet Resources (ARS), Kavango Resources (KAV), Power Metal Resources (POW), and Celsius Resources (CLA).
Landore Resources (LON:LND) and Advanced Oncotherapy (LON:AVO) are both small-cap basic materials companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, community ranking, earnings, dividends, profitability, analyst recommendations, valuation and risk.
Advanced Oncotherapy received 122 more outperform votes than Landore Resources when rated by MarketBeat users. Likewise, 60.97% of users gave Advanced Oncotherapy an outperform vote while only 57.76% of users gave Landore Resources an outperform vote.
Landore Resources is trading at a lower price-to-earnings ratio than Advanced Oncotherapy, indicating that it is currently the more affordable of the two stocks.
In the previous week, Landore Resources had 1 more articles in the media than Advanced Oncotherapy. MarketBeat recorded 1 mentions for Landore Resources and 0 mentions for Advanced Oncotherapy. Landore Resources' average media sentiment score of 0.22 beat Advanced Oncotherapy's score of 0.00 indicating that Landore Resources is being referred to more favorably in the media.
Landore Resources has a beta of -0.12, suggesting that its stock price is 112% less volatile than the S&P 500. Comparatively, Advanced Oncotherapy has a beta of 0.06, suggesting that its stock price is 94% less volatile than the S&P 500.
6.8% of Landore Resources shares are owned by institutional investors. Comparatively, 17.8% of Advanced Oncotherapy shares are owned by institutional investors. 19.2% of Landore Resources shares are owned by company insiders. Comparatively, 47.5% of Advanced Oncotherapy shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Advanced Oncotherapy's return on equity of -67.34% beat Landore Resources' return on equity.
Summary
Advanced Oncotherapy beats Landore Resources on 8 of the 12 factors compared between the two stocks.
Get Landore Resources News Delivered to You Automatically
Sign up to receive the latest news and ratings for LND and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Landore Resources Competitors List
Related Companies and Tools
